Skip to main content
All lobbying filings

OTSUKA AMERICA PHARMACEUTICAL, INC.

OTSUKA AMERICA PHARMACEUTICAL, INC. filed a Q2 report for OTSUKA AMERICA PHARMACEUTICAL, INC. on July 16, 2026.

Lobbying for OTSUKA AMERICA PHARMACEUTICAL, INC.

All filings by OTSUKA AMERICA PHARMACEUTICAL, INC. · Everything OTSUKA AMERICA PHARMACEUTICAL, INC. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 16, 2026
Expenses
$1,240,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Maryland

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Budget/Appropriations

Appropriations for the Department of Health & Human Services and the Department of Veterans Affairs, and Department of Defense.

Veterans

Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.

Medicare/Medicaid

Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)

Health Issues

Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.

Tariff (miscellaneous tariff bills)

Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem